Skip to main
TLPH
TLPH logo

Talphera Inc (TLPH) Stock Forecast & Price Target

Talphera Inc (TLPH) Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Talphera Inc. has achieved a significant milestone with FDA approval to increase the maximum number of study sites from 10 to 14, which is anticipated to expedite the enrollment process for their NEPHRO CRRT study, targeting 166 patients. The ongoing collaboration with eight original large academic institutions is expected to enhance trial recruitment, as some institutions are projected to be among the highest enrollers. Moreover, Talphera's planned protocol modifications and the intention to submit a Prior Approval Supplement to adjust the patient requirement demonstrate a strategic approach toward fulfilling regulatory obligations and achieving study completion by year-end 2025.

Bears say

Talphera Inc. reported a net loss of $3.8 million for the second quarter of 2024, translating to a loss of $0.15 per share, reflecting ongoing financial challenges. The company’s decision to lower its 2024 operating expense guidance to a range of $19-$21 million from the previous $21-$23 million suggests difficulties in managing costs amidst mounting losses. Additionally, significant risks related to trial outcomes, FDA approvals, safety concerns, and funding acquisition pose further threats to the company's financial stability and growth prospects.

Talphera Inc (TLPH) has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Talphera Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Talphera Inc (TLPH) Forecast

Analysts have given Talphera Inc (TLPH) a Strong Buy based on their latest research and market trends.

According to 2 analysts, Talphera Inc (TLPH) has a Strong Buy consensus rating as of Jul 24, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $4.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $4.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Talphera Inc (TLPH)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.